A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
NCT06037213 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-09-14
Summary
This prospective, non-interventional study is designed to evaluate the quality of life of Chinese ovarian cancer patients with long-term niraparib use in a real-world setting. Participants will complete questionnaires or accept telephone follow-up to provide information about their quality of life.
Conditions
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Principal Investigators
-
Yang Xiang, MD. · Peking Union Medical College Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-23
- Primary Completion
- 2023-12-31
- Completion
- 2024-01-31
Countries
- China
Study Locations
More Related Trials
-
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
NCT05734911 ·Status: COMPLETED
-
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT04507841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.
NCT05583799 ·Status: UNKNOWN
-
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT03326193 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000 ·Status: RECRUITING ·Phase: PHASE2
-
Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting
NCT05153603 ·Status: UNKNOWN
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study
NCT04617470 ·Status: UNKNOWN
-
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
NCT06161272 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05187208 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
NCT05311579 ·Status: UNKNOWN ·Phase: PHASE2
-
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
NCT05440578 ·Status: UNKNOWN
-
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
NCT03895788 ·Status: UNKNOWN ·Phase: PHASE1
-
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
NCT05044871 ·Status: COMPLETED ·Phase: PHASE2
-
The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer
NCT03551171 ·Status: COMPLETED ·Phase: PHASE1
-
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NCT06420973 ·Status: RECRUITING ·Phase: PHASE2
-
Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer
NCT05965141 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
NCT04861181 ·Status: TERMINATED ·Phase: PHASE4
-
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
NCT03759587 ·Status: COMPLETED ·Phase: PHASE2
-
PARPi and Ovarian Cancer Survival
NCT06838429 ·Status: NOT_YET_RECRUITING
-
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091 ·Status: UNKNOWN
-
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
NCT03759600 ·Status: COMPLETED ·Phase: PHASE2
-
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
NCT06541314 ·Status: RECRUITING ·Phase: PHASE2